In contrast, in the MIBC cohort, there was a significant decrease in macrophages and Tregs and expression of CD206, suggesting attenuation of the immunosuppressive TME in bladder cancer upon daratumumab treatment (Fig. 3C). This evidence concerns the gene MRC1 and urinary bladder cancer.